中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
Revenue Continues to Grow! TUL Announces 2024 Interim Results
2024-09-05
TUL Participates in the 2024 Diabetes Education and Management Academic Conference
2024-08-19
TUL Participates in the 21st Endocrinology Academic Conference of the Chinese Medical Association
2024-08-13
Zhuhai United Laboratories Co., Ltd. Named a “Provincial Manufacturing Single Champion Enterprise” in Guangdong Province
2024-08-13
UBT251 Injection Completes Phase Ia Clinical Study in China
2024-08-13
Mayor of Christchurch, New Zealand Visits TUL for Exchange and Cooperation
2024-08-05
TUL Ranks 16th in the “2023 Top 100 Chinese Chemical Pharmaceutical Enterprises”
2024-07-30
The United Laboratories (Inner Mongolia) Co., Ltd. Receives Marketing Approval for Bulk Medicine Tazobactam
2024-06-28
TUL Delivers a Remarkable Presence at CPHI China 2024
2024-06-25
Prev
1
...
12
13
14
15
16
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
